EMPATHY NSCLC: European Registry for Plasma-Based Molecular Profiling in Advanced NSCLC Patients

NCT07096258 · tracked via the Priya Life Science France tracker

Sponsor

Hedera Dx SA

Phase

Observational

Started

2024-06-01

Last updated

2025-07-31

Condition(s) studied

NSCLC (Advanced Non-small Cell Lung Cancer)

Study summary

The goal of this registry is to capture real-world data from plasma- and tissue-based molecular profiling, treatments, outcomes and patient-reported outcomes from patients with advanced or metastatic non-small cell lung cancer (NSCLC). The main objective of the study is to better understand the real-world clinical practice of the use and utility of molecular tumour profiling, the choice of treatment, and the outcome after such molecular profiling and treatment.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Locally advanced or metastatic, unresectable NSCLC, stages IIIB/C or IV, who have not previously been treated for this advanced disease. * Intention-to-initiate first-line tumour therapy for this advanced disease. * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2. * At least 18 years of age on the day of signing informed consent, and capable of signing informed consent. Exclusion Criteria: * Any known non-cutaneous malignancy (except for this NSCLC and early-stage non-invasive cervical cancer) that has occurred within 5 years prior to enrolment.

Primary outcome measure(s)

Actionable biomarkers — At baseline
Proportion of patients with successful molecular profiling and detectable actionable biomarkers

Trial sites (4)

Facility	City	Region	Status
Université de Lorraine	Nancy	Lorraine	Recruiting
University of Naples "Federico II"	Naples	Italy	Recruiting
General Universitario Gregorio Marañon	Madrid	Spain	Not Yet Recruiting
Hôpitaux Universitaires Genève	Geneva	Canton of Geneva	Recruiting

Other trials for the same condition

Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer Recruiting

Cisplatin (CIS) Administered As Dry Powder for Inhalation (DPI) in Patients with Stage IV Non-Small Cell Lung Cancer Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07096258 on ClinicalTrials.gov ↗ ← All trials in France